Highlights Q The Good: Sweeping reform plan does not pass because it is too costly to be financed without huge taxes. But, healthcare disinflation continues; drug companies keep their pricing increases to CPI or CPI + 1%. Health supply/device stocks unit growth flattens, but best companies still achieve 12-15% growth. Firms withdraw from marginal businesses, trim sales forces/product lines and ...

The Occasional Papers series is intended to provide a forum for examining a wide range of topics of interest to the hemophilia community. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recogni...

abstract Privacy laws for the Internet are difficult to develop and implement domestically and internationally. A clear problem is how such laws are limited to national jurisdictions. What is legal in one country may be illegal in another. Due to differences in cultures and values, and government types, it may not be possible to establish global standards and legislations to ensure privacy. Due...

  Despite the fact that human resource strategic management enjoys a worldwide maturity, it is an emergent realm of study in Iran. This novel management approach, similar to a many modern management concepts and practices, is only used in managers' diction, and as unconventional technical jargon. Aligned with the significance associated with this area and feel the need to Assess human resource...

Measuring the performance of financial holding companies Chuang-Min Chao a , Ming-Miin Yu b & Mu-Chen Chen c a Department of Business Management , National Taipei University of Technology , No. 1, Section 3, Chung-Hsiao E. Road, Taipei, 105, Taiwan, Republic of China b Department of Transportation and Navigation Science , National Taiwan Ocean University , No. 2, Pei-Ning Road, Keelung, 20224, ...

K en johnson of Pharmaceutical Research and Manufacturers of America (PhRMA) and Myrl Weinberg of the National Health Council take issue with findings from our survey of drug company–sponsored patient assistance programs (PAPs).1 Our disagreement is partly the result of a healthy debate on how best to structure our health care system. More problematic are the commentaries’ mischaracterizations ...

As recent advances have been made in developing tools to fight tuberculosis (TB), there is also a trend towards increasing advocacy by the civil society for TB research and access. One recent successful effort to increase access to treatment options for TB involved a collaborative effort to identify the need for and barriers to the use of rifapentine (RPT) use in the United States. Survey respo...

Very little real therapeutic progress was made in 2015, while a large number of unsafe or poorly evaluated drugs were authorised. The exorbitant prices for some drugs endanger universal healthcare, sometimes obliging health professionals to choose riskier options for their patients. Health professionals, health authorities and drug companies are jointly responsible for guaranteeing access to qu...

Bryant Pharmaceutical's flagship product, a popular arthritis medicine called Seflex, is selling well--but not well enough. With generic versions due on the shelves in a couple of years, the drug company is looking for a dramatic sales increase. No wonder marketing VP Laura Goldenberg feels the pressure. She knows she has to reach more consumers, but in an environment where people bombarded wit...

THIS is a sociological and not a medical book. It would be well to define and describe "The Problem of Medical Knowledge" before discussing whether social forces have effects on its formation. Certainly religion, morals, ethics and the law have their effect on the practice of medicine but that is not the subject of this book. Here the difficulties of medical knowledge are not perceived nor desc...